My ePortfolio Register   

ASH 2017 /
Daratumumab for patients with multiple myeloma

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.17
Views: 921

Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain

Prof Mateos speaks with ecancer at the 2017 ASH annual meeting about the first randomised trial looking to evaluate the use of a monoclonal antibody drug daratumumab, for treating newly diagnosed multiple myeloma. The study highlighted that adding daratumumab to one standard treatment regimen (bortezomib, melphalan, and prednisone) reduced the likelihood of disease progression or death by 50 percent.

For more information read the news story

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence